Fundraising FoxDeciphera
4 known investors
Find your way into Deciphera
Sign up to see every warm intro you have to Deciphera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Deciphera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Deciphera is a pharmaceutical company focused on developing treatments for people living with cancer. Its work centers on oncology drug development and support for patient communities.
Founders & leadership
DF
Daniel FlynnFounder and Chief Scientific Officer, Retired2003–2023Daniel Flynn is founder and former chief scientific officer of Deciphera Pharmaceuticals, where he led development of multiple oncology therapeutics including ripretinib, vimseltinib, and altiratinib. He has held positions in medicinal chemistry and drug design at Amgen, Millennium Pharmaceuticals, and other pharmaceutical firms, and serves as an adjunct professor of medicinal chemistry at the University of Kansas.
Investors · 4
Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto
How we know: Frazier Life Sciences's portfolio page · Not right? Tell us
New Leaf Venture PartnersreportedNew York
How we know: funding news · Not right? Tell us
REDMILEreportedSan Francisco
How we know: funding news · Not right? Tell us
Viking Global InvestorsreportedStamford
How we know: funding news · Not right? Tell us
Frequently asked questions
- What does Deciphera do?
- Deciphera is a pharmaceutical company focused on developing treatments for people living with cancer. Its work centers on oncology drug development and support for patient communities.
- Who founded Deciphera?
- Deciphera was founded by Daniel Flynn.
- Who are Deciphera's investors?
- Deciphera's investors include Frazier Life Sciences, New Leaf Venture Partners, REDMILE, Viking Global Investors.